OBJECTIVE: This study sought to characterize the epidemiologic, clinical, humanistic, and economic burden of patients with asthma uncontrolled by GINA Steps 4 or 5 treatment (severe, uncontrolled asthma [SUA]). METHODS: A systematic literature review adhering to PRISMA guidelines was performed. Relevant publications were searched for in MEDLINE and EMBASE from January 2004 to September 2016 and in a conference proceedings database from January 2012 to October 2016. Studies were screened using the Population, Intervention, Comparator, Outcomes, Study Design, and Time (PICOS-T) framework. Studies of SUA with observational (prospective and retrospective), randomized, or nonrandomized study designs; adult patient populations; sample sizes ≥20 patients; epidemiologic or clinical outcomes, patient-reported outcomes (PROs), or economic outcomes were included. For our analysis, SUA was defined as inadequate control of asthma, despite the use of medium- to high-dosage inhaled corticosteroids and at least one additional treatment. RESULTS: A total of 195 articles reporting unique study populations were included. Prevalence of SUA was as great as 87.4% for patients with severe asthma, although values varied depending on the criteria used to define asthma control. Compared with patients with severe asthma who were controlled, patients with SUA experienced more symptoms, night-time awakenings, rescue medication use, and worse PROs. SUA-associated costs were 3-times greater than costs for patients with severe, controlled disease. CONCLUSION: Despite the availability of approved asthma treatments, this literature analysis confirms that SUA poses a substantial epidemiologic, clinical, humanistic, and economic burden. Published data are limited for certain aspects of SUA, highlighting a need for further research.
OBJECTIVE: This study sought to characterize the epidemiologic, clinical, humanistic, and economic burden of patients with asthma uncontrolled by GINA Steps 4 or 5 treatment (severe, uncontrolled asthma [SUA]). METHODS: A systematic literature review adhering to PRISMA guidelines was performed. Relevant publications were searched for in MEDLINE and EMBASE from January 2004 to September 2016 and in a conference proceedings database from January 2012 to October 2016. Studies were screened using the Population, Intervention, Comparator, Outcomes, Study Design, and Time (PICOS-T) framework. Studies of SUA with observational (prospective and retrospective), randomized, or nonrandomized study designs; adult patient populations; sample sizes ≥20 patients; epidemiologic or clinical outcomes, patient-reported outcomes (PROs), or economic outcomes were included. For our analysis, SUA was defined as inadequate control of asthma, despite the use of medium- to high-dosage inhaled corticosteroids and at least one additional treatment. RESULTS: A total of 195 articles reporting unique study populations were included. Prevalence of SUA was as great as 87.4% for patients with severe asthma, although values varied depending on the criteria used to define asthma control. Compared with patients with severe asthma who were controlled, patients with SUA experienced more symptoms, night-time awakenings, rescue medication use, and worse PROs. SUA-associated costs were 3-times greater than costs for patients with severe, controlled disease. CONCLUSION: Despite the availability of approved asthma treatments, this literature analysis confirms that SUA poses a substantial epidemiologic, clinical, humanistic, and economic burden. Published data are limited for certain aspects of SUA, highlighting a need for further research.
Authors: Andrew Menzies-Gow; David J Jackson; Mona Al-Ahmad; Eugene R Bleecker; Francisco de Borja G Cosio Piqueras; Stephen Brunton; Giorgio Walter Canonica; Charles K N Chan; John Haughney; Steve Holmes; Janwillem Kocks; Tonya Winders Journal: Adv Ther Date: 2022-10-17 Impact factor: 4.070
Authors: Mi Ae Kim; Heung Woo Park; Byung Keun Kim; So Young Park; Ga Young Ban; Ji Hyang Lee; Jin An; Ji Su Shim; Youngsoo Lee; Ha Kyeong Won; Hwa Young Lee; Kyoung Hee Sohn; Sung Yoon Kang; So Young Park; Hyun Lee; Min Hye Kim; Jae Woo Kwon; Sun Young Yoon; Jae Hyun Lee; Chin Kook Rhee; Ji Yong Moon; Taehoon Lee; So Ri Kim; Jong Sook Park; Sang Heon Kim; Jae Won Jeong; Sang Hoon Kim; Young Il Koh; Yeon Mok Oh; An Soo Jang; Kwang Ha Yoo; You Sook Cho Journal: Allergy Asthma Immunol Res Date: 2021-05 Impact factor: 5.764
Authors: Byung Keun Kim; So Young Park; Ga Young Ban; Mi Ae Kim; Ji Hyang Lee; Jin An; Ji Su Shim; Youngsoo Lee; Ha Kyeong Won; Hwa Young Lee; Kyoung Hee Sohn; Sung Yoon Kang; So Young Park; Hyun Lee; Min Hye Kim; Jae Woo Kwon; Sun Young Yoon; Jae Hyun Lee; Chin Kook Rhee; Ji Yong Moon; Taehoon Lee; So Ri Kim; Jong Sook Park; Sang Heon Kim; Heung Woo Park; Jae Won Jeong; Sang Hoon Kim; Young Il Koh; Yeon Mok Oh; An Soo Jang; Kwang Ha Yoo; You Sook Cho Journal: Allergy Asthma Immunol Res Date: 2020-11 Impact factor: 5.764
Authors: Andrew Menzies-Gow; Gene Colice; Janet M Griffiths; Gun Almqvist; Sandhia Ponnarambil; Primal Kaur; Gennaro Ruberto; Karin Bowen; Åsa Hellqvist; May Mo; Esther Garcia Gil Journal: Respir Res Date: 2020-10-13